FDA Advisory Committees Information Collection Activities: Public Comment Request

The U.S. Food and Drug Administration (FDA) has published a notice in the Federal Register announcing a 60-day public comment period on a proposed collection of information related to its advisory committee activities. This action is taken pursuant to the Paperwork Reduction Act of 1995 (PRA), which mandates that federal agencies seek public input before collecting or extending any collection of information from the public. The specific information collection at issue pertains to the operational processes of FDA advisory committees — panels of outside experts convened to provide independent scientific and technical guidance to the Agency on regulatory decisions affecting drugs, medical devices, biologics, and other FDA-regulated products. Members of the public, including regulated industries, academic institutions, patient advocacy groups, and individuals, are invited to submit comments on the necessity, accuracy, and burden of the proposed information collection. Comments must be submitted within 60 days of the notice's publication date of March 23, 2026. This is a procedural regulatory notice and does not itself create new substantive obligations. Its primary effect is to fulfill the PRA's transparency and public participation requirements before the FDA can seek approval from the Office of Management and Budget (OMB) to continue or extend the collection.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.